Technology Development Scientist

Inivata Ltd
Job Location
Li Ka Shing Centre Robinson Way
United Kingdom
Job Description

We are looking to recruit a highly motivated, creative and logical individual to develop the next wave of innovative methods to transform cancer patient care. The successful applicant will work at the forefront of genomic technologies in developing novel methods for noninvasive analysis of cancer genomes, analysing ctDNA from plasma of cancer patients and other samples.  Assays will be developed for use in  clinical diagnostics laboratories both in the US and UK.  The role is a full time, hands-on laboratory-based position.

Key Responsibilities:

  • Work within a multidisciplinary team to help optimise eTAm-Seq assays for plasma sequencing and help develop enhanced NGS-based methods for ctDNA analysis
  • Perform studies to assess assay sensitivity and specificity
  • Design and optimise new cancer panels
  • Assist in automating and streamlining workflows in both current and future pipelines
  • Help to develop SOPs for novel NGS-based methods and assist in transitioning assays for use into the clinical diagnostic laboratories
  • Development of LIMs processes for updated assays
  • Review literature to develop new concepts to improve ctDNA sequencing


  • A BSc or similar degree in Biology, Genetics, Chemistry or other field related to next generation sequencing and cancer genetics (essential)
  • A PhD in Biology, Genetics, Chemistry or other field related to next generation sequencing and cancer genetics (desirable)


  • A minimum of 2 years’ molecular biology laboratory experience or similar (essential)
  • Experience in product development and design control (desirable)
  • Strong problem solving abilities (essential)
  • Experience of nucleic acid extraction, DNA quantification and PCR analysis (desirable)
  • Experience with next generation sequencing library preparation (desirable)
  • Experience with molecular biology method development (desirable)
  • Experience in the field of cancer genetics (desirable)
  • Experience working to ISO 15189:2012, ISO 13485 or GCLP standards in a clinical diagnostic lab (desirable)
  • Excellent organisational, time management and communication skills (essential)
  • Excellent record keeping skills for maintaining detailed laboratory notebook records (essential)
  • Experience working with and updating a LIMs system (desirable)
How to Apply

Please send your CV, including a covering letter to: quoting: 010 Technology Development Scientist in the subject line.

No agencies please.

The closing date for applications is 18th November 2016.

About Our Organization

Inivata, a global clinical cancer genomics company, is transforming personalised healthcare in oncology by utilising the precision of circulating tumour (ctDNA) analysis.  Using a simple blood sample, ctDNA testing is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment.  Inivata’s proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge.  Inivata’s platform brings together Next-Generation sequencing (NGS) technology with proprietary algorithms and databases that guide genomic profiles to clinical outcomes.   Inivata’s InVision® ctDNA assay provides a highly sensitive analysis of a strategically selected gene panel to identify actionable mutations for oncologists to treat their patients optimally.  Inivata recently completed a highly successful Series A fundraising of £31.5m to accelerate clinical studies and commercialise the company’s first products.

Inivata is a fast-paced, dynamic startup company with founders who are pioneers in the field of ctDNA analysis.  We are a dedicated team with strong foundations and leadership and are all passionate about modernising cancer care and treatment for patients.  Inivata employees have both drive and determination to work successfully as individuals and as a team to revolutionise cancer care.  As part of this role there will be international travel and collaboration between the US/UK offices that brings a global-community feel to Inivata as we tackle the universal disturbance of cancer together with our most advanced technology.

An analysis appearing in PeerJ finds that social media mentions of a paper may lead to increased citations.

NIH's Michael Lauer looks at the number of grants, their amount, and funding success rates at the agency for last year.

At Nature, Johns Hopkins' Gundula Bosch describes her graduate program that aims to get doctoral students thinking about the big picture.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.